A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + AntiHER2 Therapy + Endocrine Therapy vs. AntiHER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2Positive Metastatic Breast Cancer

Project: Research

StatusActive
Effective start/end date8/02/197/02/24